Download Financial/Commercial Relationships DISCLOSURES

Name of Reviewer(s):
Laurie Gaspar, MD –Nothing to Disclose
Name of Planner(s):
Carlos Ferreira
Pia Hirsch-Nothing to Disclose
Name of Activity:
Date of Activity:
Faculty/Speaker(s)Disclosure:
COI Resolution: Ensure a balanced
discussion of alternative. Do not use
trade names. Do not refer to
company names or logos. Do not
recommend therapies.
“All planning committee members’
and/or faculty’s identified conflicts
of interest pertaining to this activity
were resolved prior to the activity.”
Type of Activity:
Are there Commercial Supporters
for this activity?
Carlos Ferreira-Nothing to Disclose
Management of ALK Patients With NSCLC: A Multidisciplinary Approach
09/12/2016
Speaker: Alice Shaw, MD, PhD-Advisory Board: Pfizer, Novartis,
Genentech/Roche,
Nothing to Disclose Ariad, EMD Serono, Blueprint medicine, LOXO.
Consultant: Ignyta, Daiichi-sankyo, Taiho.
Speaker: Lunette Sholl, MD-Advisory Board: Genentech/Roche.
Speaker: Leora Horn, MD-Advisory Boar/Paid Consultant: BMS, BI, Xcovery,
Abbvie, Genentech, Lilly, Merck
Live Course
Yes
No
Internet Live Course (Webinar)
Internet Enduring Material
If yes, please list: Unrestricted grant support by Ariad
Financial/Commercial Relationships DISCLOSURES
A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of
CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12
months with a commercial interest that produces, markets, re-sells, or distributes health care goods or
services consumed by, or used, on patients that benefits the individual in any financial amount and
therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual
property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other
ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits
are usually associated with roles such as employment, management position, independent contractor
(including contracted research and clinical trials), consulting, speaking and teaching, membership on
advisory committees or review panels, board membership, and other activities for which remuneration is
received or expected.
This IASLC CME educational activity was planned and developed to: uphold academic standards to
ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health
information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include
a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents
are discussed or referenced.
IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest
were identified, reviewed and resolved from all individuals involved in the development or able to influence
and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an
educational activity being delivered to learners. Any individual who failed or refused to disclose
relevant financial relationships was disqualified from this CME activity and removed from any of IASLC
CME activity presentation.
All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC
Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of
Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient
care recommendations. IASLC CME is committed to providing its learners with high-quality CME
activities and related materials that promote improvements or quality in health care and not a specific
proprietary business interest of a commercial entity.
The following Financial Disclosures are from the, reviewers and planning committee members (et.al.)
their spouse/life partner have disclosed regarding financial interest/arrangement or affiliation with any
commercial interests that produce, market, re-sell, or distribute healthcare goods or services for patients
that are relevant to this presentation(s) or that have provided commercial support for this continuing
medical education activity: HAVE NOTHING TO DISCLOSE.
Speakers Financial Disclosures:
Speaker: Alice Shaw, MD, PhD-Advisory Board: Pfizer, Novartis, Genentech/Roche, Ariad, EMD
Serono, Blueprint medicine, LOXO. Consultant: Ignyta, Daiichi-sankyo, Taiho.
Speaker: Lunette Sholl, MD-Advisory Board: Genentech/Roche.
Speaker: Leora Horn, MD-Advisory Boar/Paid Consultant: BMS, BI, Xcovery, Abbvie, Genentech,
Lilly, Merck
CREDIT STATEMENT
IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide
continuing medical education for physicians.
IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1
Credits™. Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
FINANCIAL SUPPORT
Unrestricted grant support for this webinar by Ariad.
GOAL & PURPOSE
This presentation will discuss the role of advanced imaging techniques in evaluating lung cancer,
including:
Practical Approaches to ALK Rearrangement Detection - Lynette Sholl, MD
This presentation will address the pros and cons of in situ, immunohistochemical and molecular
approaches to ALK rearrangement detection in lung cancers and will discuss the evolving guidelines for
for ALK testing.
Systemic Treatment Options for ALK-Positive NSCLC - Leora Horn, MD
This presentation will address current state-of-the art first line treatment options for patients with ALK positive NSCLC.
Overcoming resistance to ALK Inhibitors - Alice Shaw, MD
This presentation will review mechanisms of resistance to first and next generation ALK inhibitors, and
discuss new and emerging treatment options for patients who develop resistance to one or more ALK
inhibitors.
TARGET AUDIENCE
This CME live webinar series is designed to meet the educational needs of healthcare professionals who
diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons,
pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and
physicians' assistants.
LEARNING OBJECTIVES

Define systemic therapy options for patients with ALK-positive NSCLC.



Describe the mechanisms of resistance to first and next generation ALK inhibitors.
Demonstrate the evolving state-of-the art of treatment of patients with ALK -positive NSCLC
who are resistant to one or more ALK inhibitors.
Monitor major, ongoing and planned clinical trials for patients with ALK-positive NSCLC.
DISCLAMER
Participants have an implied responsibility to use the newly acquired information to enhance patient
outcomes and their own professional development. The information presented in this activity is not
meant to serve as a guideline for patient management. Any procedures, medications, or other courses of
diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any
applicable manufacturer’s product information, and comparison with recommendations of other
authorities.
Thank you for your participation.